BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

606 related articles for article (PubMed ID: 15100667)

  • 1. Effect of specific immunotherapy added to pharmacologic treatment and allergen avoidance in asthmatic patients allergic to house dust mite.
    Maestrelli P; Zanolla L; Pozzan M; Fabbri LM;
    J Allergy Clin Immunol; 2004 Apr; 113(4):643-9. PubMed ID: 15100667
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of sublingual immunotherapy efficacy in children with house dust mite-induced allergic asthma optimally controlled by pharmacologic treatment and mite-avoidance measures.
    Pham-Thi N; Scheinmann P; Fadel R; Combebias A; Andre C
    Pediatr Allergy Immunol; 2007 Feb; 18(1):47-57. PubMed ID: 17295799
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Effect of 1-year specific immunotherapy with standardized house dust mite vaccine on mild to moderate allergic asthmatic patients].
    Wang HY; Lin XP; Hao CL; Zhang CQ; Sun BQ; Zheng JP; Chen P; Sheng JY; Wu A; Zhong NS
    Zhonghua Jie He He Hu Xi Za Zhi; 2006 Oct; 29(10):679-87. PubMed ID: 17129496
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sublingual immunotherapy in children with allergic rhinoconjunctivitis mono-sensitized to house-dust-mites: a double-blind-placebo-controlled randomised trial.
    Aydogan M; Eifan AO; Keles S; Akkoc T; Nursoy MA; Bahceciler NN; Barlan IB
    Respir Med; 2013 Sep; 107(9):1322-9. PubMed ID: 23886432
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical efficacy and immunological mechanisms of sublingual and subcutaneous immunotherapy in asthmatic/rhinitis children sensitized to house dust mite: an open randomized controlled trial.
    Eifan AO; Akkoc T; Yildiz A; Keles S; Ozdemir C; Bahceciler NN; Barlan IB
    Clin Exp Allergy; 2010 Jun; 40(6):922-32. PubMed ID: 20100188
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Depigmented and polymerised house dust mite allergoid: allergen content, induction of IgG4 and clinical response.
    Gallego MT; Iraola V; Himly M; Robinson DS; Badiola C; García-Robaina JC; Briza P; Carnés J
    Int Arch Allergy Immunol; 2010; 153(1):61-9. PubMed ID: 20357486
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A double-blind, placebo-controlled study of house dust mite immunotherapy in Chinese asthmatic patients.
    Wang H; Lin X; Hao C; Zhang C; Sun B; Zheng J; Chen P; Sheng J; Wu A; Zhong N
    Allergy; 2006 Feb; 61(2):191-7. PubMed ID: 16409195
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of long-term sublingual immunotherapy as an adjunct to pharmacotherapy in house dust mite-allergic children with asthma.
    Ozdemir C; Yazi D; Gocmen I; Yesil O; Aydogan M; Semic-Jusufagic A; Bahceciler NN; Barlan IB
    Pediatr Allergy Immunol; 2007 Sep; 18(6):508-15. PubMed ID: 17680909
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevention of allergic disease in childhood: clinical and epidemiological aspects of primary and secondary allergy prevention.
    Halken S
    Pediatr Allergy Immunol; 2004 Jun; 15 Suppl 16():4-5, 9-32. PubMed ID: 15125698
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Analysis of the efficacy of specific immunotherapy with house-dust mite extracts in adults with allergic rhinitis and/or asthma].
    Polzehl D; Keck T; Riechelmann H
    Laryngorhinootologie; 2003 Apr; 82(4):272-80. PubMed ID: 12717603
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical and immunologic effects of sublingual immunotherapy in asthmatic children sensitized to mites: a double-blind, randomized, placebo-controlled study.
    Lue KH; Lin YH; Sun HL; Lu KH; Hsieh JC; Chou MC
    Pediatr Allergy Immunol; 2006 Sep; 17(6):408-15. PubMed ID: 16925685
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical effectiveness of a mite allergen-impermeable bed-covering system in asthmatic mite-sensitive patients.
    van den Bemt L; van Knapen L; de Vries MP; Jansen M; Cloosterman S; van Schayck CP
    J Allergy Clin Immunol; 2004 Oct; 114(4):858-62. PubMed ID: 15480327
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of a House Dust Mite Sublingual Allergen Immunotherapy Tablet in Adults With Allergic Asthma: A Randomized Clinical Trial.
    Virchow JC; Backer V; Kuna P; Prieto L; Nolte H; Villesen HH; Ljørring C; Riis B; de Blay F
    JAMA; 2016 Apr; 315(16):1715-25. PubMed ID: 27115376
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Standardized quality (SQ) house dust mite sublingual immunotherapy tablet (ALK) reduces inhaled corticosteroid use while maintaining asthma control: a randomized, double-blind, placebo-controlled trial.
    Mosbech H; Deckelmann R; de Blay F; Pastorello EA; Trebas-Pietras E; Andres LP; Malcus I; Ljørring C; Canonica GW
    J Allergy Clin Immunol; 2014 Sep; 134(3):568-575.e7. PubMed ID: 24797423
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of sublingual immunotherapy with high-dose mite extracts in asthma: a multi-center, double-blind, randomized, and placebo-controlled study in Taiwan.
    Niu CK; Chen WY; Huang JL; Lue KH; Wang JY
    Respir Med; 2006 Aug; 100(8):1374-83. PubMed ID: 16403616
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Steroid-sparing effect of subcutaneous SQ-standardised specific immunotherapy in moderate and severe house dust mite allergic asthmatics.
    Blumberga G; Groes L; Haugaard L; Dahl R
    Allergy; 2006 Jul; 61(7):843-8. PubMed ID: 16792582
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Successful management of mite-allergic asthma with modified extracts of Dermatophagoides pteronyssinus and Dermatophagoides farinae in a double-blind, placebo-controlled study.
    García-Robaina JC; Sánchez I; de la Torre F; Fernández-Caldas E; Casanovas M
    J Allergy Clin Immunol; 2006 Nov; 118(5):1026-32. PubMed ID: 17088125
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Control of exposure to mite allergen and allergen-impermeable bed covers for adults with asthma.
    Woodcock A; Forster L; Matthews E; Martin J; Letley L; Vickers M; Britton J; Strachan D; Howarth P; Altmann D; Frost C; Custovic A;
    N Engl J Med; 2003 Jul; 349(3):225-36. PubMed ID: 12867606
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of A-type CpG oligodeoxynucleotides as an adjuvant in allergen-specific immunotherapy in humans: a phase I/IIa clinical trial.
    Senti G; Johansen P; Haug S; Bull C; Gottschaller C; Müller P; Pfister T; Maurer P; Bachmann MF; Graf N; Kündig TM
    Clin Exp Allergy; 2009 Apr; 39(4):562-70. PubMed ID: 19226280
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the efficacy of subcutaneous and sublingual immunotherapy in mite-sensitive patients with rhinitis and asthma--a placebo controlled study.
    Mungan D; Misirligil Z; Gürbüz L
    Ann Allergy Asthma Immunol; 1999 May; 82(5):485-90. PubMed ID: 10353581
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.